

Dissecting the Decision: Investigators Discuss Available and Emerging Data on the Use of PARP Inhibitors in Ovarian Cancer and Other Novel Systemic Strategies Under Development for Gynecologic Cancers

QUESTIONS (PLEASE CIRCLE ANSWER):

1. Current guidelines recommend that _____ undergo BRCA testing.
 - a. All patients with epithelial OC
 - b. Only patients of Ashkenazi Jewish descent
 - c. Only patients with a strong family history of breast cancer or OC at a young age
2. The incidence of homologous recombination deficiency in patients with high-grade serous OC is estimated to be approximately _____.
 - a. 20%
 - b. 30%
 - c. 50%
3. Study 19, investigating olaparib maintenance after platinum-based chemotherapy in patients with platinum-sensitive, recurrent, serous OC, reported a statistically significant improvement in overall survival for patients who received olaparib compared to placebo.
 - a. True
 - b. False
4. In which of the following subgroups of patients with platinum-sensitive recurrent OC did niraparib maintenance therapy provide a significant progression-free survival benefit compared to placebo on the Phase III ENGOT-OV16/NOVA trial?
 - a. Patients with germline BRCA mutations
 - b. Patients without germline BRCA mutations
 - c. Patients with HRD positivity and no germline BRCA mutations
 - d. All of the above
 - e. Both b and c
5. Thrombocytopenia that occurs early (in the first 2 cycles) is a characteristic toxicity of _____.
 - a. Olaparib
 - b. Niraparib
 - c. Rucaparib
6. Rucaparib was recently approved by the FDA for patients with deleterious BRCA-mutated advanced OC who have received _____.
 - a. Two or more lines of chemotherapy
 - b. Three or more lines of chemotherapy
 - c. No chemotherapy
7. The Phase III SOLO2 trial evaluating olaparib monotherapy versus placebo as maintenance therapy for patients with platinum-sensitive, relapsed OC _____.
 - a. Demonstrated a statistically significant improvement in progression-free survival with olaparib
 - b. Included only patients with BRCA-mutant disease
 - c. Evaluated the capsule formulation of olaparib
 - d. All of the above
 - e. Both a and b
8. Bevacizumab has been FDA approved for platinum-sensitive, recurrent OC in combination with which of the following chemotherapy options?
 - a. Carboplatin/paclitaxel
 - b. Carboplatin/gemcitabine
 - c. Topotecan hydrochloride
 - d. All of the above
 - e. Both a and b
9. Mirvetuximab soravtansine (IMGN853) is _____.
 - a. An anti-angiogenic agent
 - b. An antibody-drug conjugate
 - c. A PARP inhibitor
10. The Phase III AIM2CERV study is investigating listeria-based HPV immunotherapy as adjuvant treatment after chemoradiation therapy for patients with advanced _____.
 - a. Cervical cancer
 - b. Endometrial cancer
 - c. Ovarian cancer